Bayer completes rolling submission for darolutamide in U.S. (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - February 27, 2019 Category: Pharmaceuticals Source Type: news

Bayer proposes dividend for 2018 of 2.80 euros per share
Total dividend payment: record high of 2.611 billion euros (Source: Bayer Company News)
Source: Bayer Company News - February 26, 2019 Category: Pharmaceuticals Source Type: news

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) (for specialized target groups only)
Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents / Bayer to be solely responsible for the global development and commercialization of both larotrectinib and BAY 2731954 (LOXO-195) / Co-Promotion in the U.S. to be converted into exclusive commercialization by Bayer / Larotrectinib was approved in November 2018 in the U.S. under the brand name VITRAKVI ® as the first TRK inhibitor for patients with advanced solid tumors harboring an NTRK gene fusion; filings in Europe and other regions underway (Source: Bayer Company News)
Source: Bayer Company News - February 15, 2019 Category: Pharmaceuticals Source Type: news

Bayer & #8217;s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Statistically significant improvement in metastasis-free survival (MFS), with a median MFS of 40.4 months with darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT (18.4 months) / Positive trend in overall survival with a 29% reduction in risk of death at interim analysis (P=0.045) / Incidence of treatment-emergent adverse events was similar for darolutamide plus ADT and placebo plus ADT / Health-related quality of life was maintained / First results from the Phase III ARAMIS trial with the androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinic...
Source: Bayer Company News - February 14, 2019 Category: Pharmaceuticals Source Type: news

Bayer expands digital innovation pipeline at The Climate Corporation to bring breakthrough digital tools to more farmers
(Source: Bayer Company News)
Source: Bayer Company News - January 8, 2019 Category: Pharmaceuticals Source Type: news

Bayer to drive value creation as company pursues ambitious growth targets through 2022
Company strongly positioned to benefit from key megatrends / Through 2022, Bayer aims to grow sales by 4 percent, EBITDA before special items by 9 percent and free cash flow by 18 percent annually on average / Adjusted EBITDA margin targets for 2022: Crop Science to exceed 30 percent, Pharmaceuticals to hit more than 35 percent, and Consumer Health to reach approximately 24 percent (Source: Bayer Company News)
Source: Bayer Company News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
The software in development intends to support clinical decision-making of chronic thromboembolic pulmonary hypertension– a progressive and life-threatening condition (Source: Bayer Company News)
Source: Bayer Company News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability
Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany / Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition / A portion of the contributions to be reinvested in core businesses / Total one-time costs expected at a factor of 1.7 times annual contributions / Core earnings per share expected to increase by around 1 euro to 6.80 euros in 201...
Source: Bayer Company News - November 29, 2018 Category: Pharmaceuticals Source Type: news

Bayer receives EU approval for its hemophilia A treatment Jivi ® (for specialized target groups only)
The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time (Source: Bayer Company News)
Source: Bayer Company News - November 27, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA approves Larotrectinib, the first TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion (for specialized target groups only)
First treatment with a tumor-agnostic indication at the time of initial FDA approval / Larotrectinib approved under the brand name Vitrakvi ® / 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in adults and children / Adverse events (AEs) of any grade observed in more than 20 percent of patients, regardless of attribution, included increased ALT (4 5%), increased AST (45%), anemia (42%), fatigue (37%), nausea (29%), dizziness (28%), cough (26%), vomiting (26%), constipation (23%), and diarrhea (22%) (Source: Bayer Company News)
Source: Bayer Company News - November 27, 2018 Category: Pharmaceuticals Source Type: news

Bayer: Good performance in a challenging environment, Group outlook confirmed
Group sales increase by 1.9 percent (Fx& portfolio adj.) to 9.905 billion euros / EBITDA before special items level year on year at 2.202 billion euros / Business performance at Pharmaceuticals remains strong / Consumer Health with increase in sales (Fx& portfolio adj.), while currency effects weigh on earnings / Crop Science posts substantial rise in sales and earnings due to acquisition– successful start to integration process / Sales and earnings of Animal Health decline following a strong second quarter / One-time gain (before taxes) of roughly 3.9 billion euros from divestments / Net income 2.886 billion euros /...
Source: Bayer Company News - November 13, 2018 Category: Pharmaceuticals Source Type: news

Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint (for specialized target groups only)
The safety and tolerability observed in the trial were consistent with previously published data on darolutamide (Source: Bayer Company News)
Source: Bayer Company News - October 24, 2018 Category: Pharmaceuticals Source Type: news